Skip to main content

Cardlytics Inc

For the period ended Mar 31, 2024. Filed May 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations (Unaudited)

(Amounts in thousands, except per share amounts)

Three Months EndedMarch 31,
20242023
Revenue$67,608$64,331
Costs and expenses:
Partner Share and other third-party costs30,54333,384
Delivery costs6,1736,424
Sales and marketing expense14,11813,948
Research and development expense13,04811,564
General and administration expense14,48513,070
Acquisition, integration and divestiture cost—1,723
Change in contingent consideration5,817(34,584)
Depreciation and amortization expense6,2506,575
Total costs and expenses90,43452,104
Operating (Loss) Income(22,826)12,227
Other expense (income):
Interest expense, net(819)(8)
Foreign currency (loss) gain(630)1,389
Total other (expense) income(1,449)1,381
(Loss) Income before income taxes(24,275)13,608
Net (Loss) Income$(24,275)$13,608
Net (Loss) Income per share, basic$(0.56)$0.41
Net (Loss) Income per share, diluted$(0.56)$0.40
Weighted-average common shares outstanding, basic43,24833,595
Weighted-average common shares outstanding, diluted43,24836,727
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.